Cognition Therapeutics News

Express News | Cognition Therapeutics To Be Issued US Patent Number 11,981,636 Titled "COMPOSITIONS FOR TREATING NEURODEGENERATIVE DISEASES (INCLUDING ALZHEIMER'S DISEASE AND COGNITIVE DECLINE)"

BenzingaMay 13 14:02 ET

Oppenheimer Sticks to Their Buy Rating for Cognition Therapeutics (CGTX)

TipRanksMay 13 07:55 ET

Cognition Therapeutics | 10-Q: Quarterly report

Futu NewsMay 7 07:49 ET · Announcements

Express News | Cognition Therapeutics Inc: Topline Results From Shine Study in Mild-to-Moderate Alzheimer's Expected Mid-2024

ReutersMay 7 07:30 ET

Express News | Cognition Therapeutics Reports Financial Results for the First Quarter 2024 and Provides Business Update

ReutersMay 7 07:30 ET

Express News | Cognition Therapeutics Q1 Operating Expenses USD 14.102 Million

ReutersMay 7 07:30 ET

Express News | Cognition Therapeutics Q1 Income From Operations USD -14.102 Million

ReutersMay 7 07:30 ET

Cognition Therapeutics 1Q Loss/Shr 27c >CGTX

Cognition Therapeutics 1Q Loss/Shr 27c >CGTX

Dow JonesMay 7 07:30 ET

Sage Growth Partners Announces Marketing Partnership With Cognition Corporation

Baltimore-based healthcare growth strategy and marketing firm to support strategic marketing, thought leadership, and lead acquisition services BALTIMORE, April 30, 2024 /PRNewswire/ -- Sage Growth

PR NewswireApr 30 08:27 ET

Express News | Cognition Therapeutics Completes Enrollment In Phase 2 SHIMMER Study Of CT1812 In Mild-To-Moderate Dementia With Lewy Bodies, Top-line Results Are Expected In 2H Of 2024 After The Last Participants Have Completed Six Months Of Treatment

BenzingaApr 29 07:32 ET

Express News | Cognition Therapeutics Inc: Top-Line Results Are Expected in Second Half of 2024 After Last Participants Have Completed Six Months of Treatment

ReutersApr 29 07:31 ET

Express News | Cognition Therapeutics Completes Enrollment in Phase 2 Shimmer Study of Ct1812 in Mild-to-Moderate Dementia With Lewy Bodies

ReutersApr 29 07:31 ET

12 Health Care Stocks Moving In Monday's After-Market Session

GainersNuwellis (NASDAQ:NUWE) stock rose 46.8% to $0.48 during Monday's after-market session. The company's market cap stands at $3.2 million. Sensei Biotherapeutics (NASDAQ:SNSE) stock rose 7.42% to

BenzingaApr 22 16:31 ET

Cognition Therapeutics KOL Event Provided Platform for Valuable Discussion of Current Therapeutic Options and Need for Additional Options to Treat Alzheimer's Disease

PURCHASE, N.Y., April 22, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the "Company" or "Cognition") (NASDAQ:CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders, provided

GlobeNewswireApr 22 07:30 ET

Analysts Are Bullish on Top Healthcare Stocks: Halozyme (HALO), Cognition Therapeutics (CGTX)

TipRanksApr 16 07:41 ET

Cognition Therapeutics to Present at the Needham Virtual Healthcare Conference

PURCHASE, N.Y., April 02, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (the "Company" or "Cognition") (NASDAQ:CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders, announced

GlobeNewswireApr 2 07:30 ET

Cognition Therapeutics to Host Virtual KOL Event on the Evolving Landscape in Alzheimer's Disease on April 12, 2024

NEW YORK, April 01, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (the "Company" or "Cognition") (NASDAQ: CGTX), a clinical stage company developing drugs that treat neurodegenerative disord

GlobeNewswireApr 1 07:30 ET

Express News | B. Riley Securities Reiterates Buy on Cognition Therapeutics, Maintains $5 Price Target

Moomoo 24/7Mar 28 11:58 ET

Buy Rating Affirmed for Cognition Therapeutics Amid Promising CT1812 Clinical Trials

TipRanksMar 28 07:35 ET

Cognition Therapeutics, Inc. (NASDAQ:CGTX) Q4 2023 Earnings Call Transcript

Yahoo FinanceMar 27 09:31 ET